Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP)

Yasuhide Kitagawa, Satoru Ueno, Kouji Izumi, Atsushi Mizokami, Shiro Hinotsu, Hideyuki Akaza, Mikio Namiki

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: The aim of this study was to investigate whether nadir prostate-specific antigen (PSA) level and time to PSA nadir (TTN) are independent prognostic factors equivalent to the pretreatment factors in the data of the Japan Study Group of Prostate Cancer registry, which is a large, multicenter, population-based database of patients undergoing primary androgen deprivation therapy (PADT). Methods: A total of 10,958 patients treated with PADT were enrolled into the present study. Univariate and multivariate Cox proportional hazards regression analysis and Kaplan-Meier analysis were used to evaluate the associations of PSA nadir level and TTN with progression-free survival (PFS) and overall survival (OS), adjusting for the pretreatment factors adopted in the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score. Results: Of the 10,958 patients, 3,451 (31.5 %) had lymph node and/or distant metastases. The median PSA level was 27.0 ng/ml before treatment, and the nadir PSA level in 6,983 patients (63.7 %) reached below 0.2 ng/ml. Disease progression occurred in 4,736 cases, and 2,163 patients died during a mean follow-up period of 3.86 years. Nadir PSA level and TTN were independent prognostic factors, similar to the pretreatment factors adopted in the J-CAPRA score. The probabilities of PFS and OS showed significant differences among the groups categorized by the combination of nadir PSA level and TTN in all J-CAPRA risk stratifications. Conclusions: The present study demonstrated that nadir PSA level and TTN are strong predictors in patients undergoing PADT in a large-scale prospective cohort study.

Original languageEnglish
Pages (from-to)673-679
Number of pages7
JournalJournal of Cancer Research and Clinical Oncology
Volume140
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Prostate-Specific Antigen
Androgens
Cohort Studies
Prospective Studies
Prostatic Neoplasms
Japan
Therapeutics
Disease-Free Survival
Survival
Kaplan-Meier Estimate
Registries
Disease Progression
Lymph Nodes
Regression Analysis
Databases
Neoplasm Metastasis
Population

Keywords

  • Nadir PSA level
  • Outcome predictor
  • Primary androgen deprivation
  • Prostate cancer
  • Time to PSA nadir

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP). / Kitagawa, Yasuhide; Ueno, Satoru; Izumi, Kouji; Mizokami, Atsushi; Hinotsu, Shiro; Akaza, Hideyuki; Namiki, Mikio.

In: Journal of Cancer Research and Clinical Oncology, Vol. 140, No. 4, 2014, p. 673-679.

Research output: Contribution to journalArticle

@article{0d3fe3928c7d4f79810f00de45ddc733,
title = "Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP)",
abstract = "Purpose: The aim of this study was to investigate whether nadir prostate-specific antigen (PSA) level and time to PSA nadir (TTN) are independent prognostic factors equivalent to the pretreatment factors in the data of the Japan Study Group of Prostate Cancer registry, which is a large, multicenter, population-based database of patients undergoing primary androgen deprivation therapy (PADT). Methods: A total of 10,958 patients treated with PADT were enrolled into the present study. Univariate and multivariate Cox proportional hazards regression analysis and Kaplan-Meier analysis were used to evaluate the associations of PSA nadir level and TTN with progression-free survival (PFS) and overall survival (OS), adjusting for the pretreatment factors adopted in the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score. Results: Of the 10,958 patients, 3,451 (31.5 {\%}) had lymph node and/or distant metastases. The median PSA level was 27.0 ng/ml before treatment, and the nadir PSA level in 6,983 patients (63.7 {\%}) reached below 0.2 ng/ml. Disease progression occurred in 4,736 cases, and 2,163 patients died during a mean follow-up period of 3.86 years. Nadir PSA level and TTN were independent prognostic factors, similar to the pretreatment factors adopted in the J-CAPRA score. The probabilities of PFS and OS showed significant differences among the groups categorized by the combination of nadir PSA level and TTN in all J-CAPRA risk stratifications. Conclusions: The present study demonstrated that nadir PSA level and TTN are strong predictors in patients undergoing PADT in a large-scale prospective cohort study.",
keywords = "Nadir PSA level, Outcome predictor, Primary androgen deprivation, Prostate cancer, Time to PSA nadir",
author = "Yasuhide Kitagawa and Satoru Ueno and Kouji Izumi and Atsushi Mizokami and Shiro Hinotsu and Hideyuki Akaza and Mikio Namiki",
year = "2014",
doi = "10.1007/s00432-014-1612-8",
language = "English",
volume = "140",
pages = "673--679",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP)

AU - Kitagawa, Yasuhide

AU - Ueno, Satoru

AU - Izumi, Kouji

AU - Mizokami, Atsushi

AU - Hinotsu, Shiro

AU - Akaza, Hideyuki

AU - Namiki, Mikio

PY - 2014

Y1 - 2014

N2 - Purpose: The aim of this study was to investigate whether nadir prostate-specific antigen (PSA) level and time to PSA nadir (TTN) are independent prognostic factors equivalent to the pretreatment factors in the data of the Japan Study Group of Prostate Cancer registry, which is a large, multicenter, population-based database of patients undergoing primary androgen deprivation therapy (PADT). Methods: A total of 10,958 patients treated with PADT were enrolled into the present study. Univariate and multivariate Cox proportional hazards regression analysis and Kaplan-Meier analysis were used to evaluate the associations of PSA nadir level and TTN with progression-free survival (PFS) and overall survival (OS), adjusting for the pretreatment factors adopted in the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score. Results: Of the 10,958 patients, 3,451 (31.5 %) had lymph node and/or distant metastases. The median PSA level was 27.0 ng/ml before treatment, and the nadir PSA level in 6,983 patients (63.7 %) reached below 0.2 ng/ml. Disease progression occurred in 4,736 cases, and 2,163 patients died during a mean follow-up period of 3.86 years. Nadir PSA level and TTN were independent prognostic factors, similar to the pretreatment factors adopted in the J-CAPRA score. The probabilities of PFS and OS showed significant differences among the groups categorized by the combination of nadir PSA level and TTN in all J-CAPRA risk stratifications. Conclusions: The present study demonstrated that nadir PSA level and TTN are strong predictors in patients undergoing PADT in a large-scale prospective cohort study.

AB - Purpose: The aim of this study was to investigate whether nadir prostate-specific antigen (PSA) level and time to PSA nadir (TTN) are independent prognostic factors equivalent to the pretreatment factors in the data of the Japan Study Group of Prostate Cancer registry, which is a large, multicenter, population-based database of patients undergoing primary androgen deprivation therapy (PADT). Methods: A total of 10,958 patients treated with PADT were enrolled into the present study. Univariate and multivariate Cox proportional hazards regression analysis and Kaplan-Meier analysis were used to evaluate the associations of PSA nadir level and TTN with progression-free survival (PFS) and overall survival (OS), adjusting for the pretreatment factors adopted in the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score. Results: Of the 10,958 patients, 3,451 (31.5 %) had lymph node and/or distant metastases. The median PSA level was 27.0 ng/ml before treatment, and the nadir PSA level in 6,983 patients (63.7 %) reached below 0.2 ng/ml. Disease progression occurred in 4,736 cases, and 2,163 patients died during a mean follow-up period of 3.86 years. Nadir PSA level and TTN were independent prognostic factors, similar to the pretreatment factors adopted in the J-CAPRA score. The probabilities of PFS and OS showed significant differences among the groups categorized by the combination of nadir PSA level and TTN in all J-CAPRA risk stratifications. Conclusions: The present study demonstrated that nadir PSA level and TTN are strong predictors in patients undergoing PADT in a large-scale prospective cohort study.

KW - Nadir PSA level

KW - Outcome predictor

KW - Primary androgen deprivation

KW - Prostate cancer

KW - Time to PSA nadir

UR - http://www.scopus.com/inward/record.url?scp=84899492876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899492876&partnerID=8YFLogxK

U2 - 10.1007/s00432-014-1612-8

DO - 10.1007/s00432-014-1612-8

M3 - Article

VL - 140

SP - 673

EP - 679

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 4

ER -